Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas […]
Former Director of Security of the Israeli Defense Establishment Nir Ben Moshe Joining ParaZero
Ben Moshe is set to join ParaZero as a specialist advisor, utilizing his extensive network in defense and homeland security […]
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy […]
Save Foods: Nitrousink Commenced Controlled Trial for the Reduction of Greenhouse Gas Emissions
Neve Yarak, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) — Save Foods, Inc. (NASDAQ: SVFD) (FSE:80W), an agri-food tech leader, announced […]
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing […]
Osisko Development Intercepts 443.64 G/T Gold Over 1.19 Meters in Underground Sampling at Trixie, Tintic Project
MONTREAL, Dec. 21, 2023 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) is […]
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share Following the close […]
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe […]
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
– MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked […]
Clene Provides Update on ALS Clinical Development Meeting With FDA
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its […]
